Decoding 6 Analyst Evaluations For Blueprint Medicines
Decoding 6 Analyst Evaluations For Blueprint Medicines
解碼藍圖藥物的 6 項分析師評估
During the last three months, 6 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.
在過去的三個月中，6位分析師分享了他們對Blueprint Medicines（納斯達克股票代碼：BPMC）的評估，揭示了從看漲到看跌的不同前景。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他們最近的評級，簡要介紹了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $95.67, a high estimate of $114.00, and a low estimate of $65.00. Surpassing the previous average price target of $56.00, the current average has increased by 70.84%.
在對12個月目標股價的評估中，分析師公佈了對藍圖藥品的見解，將平均目標價定爲95.67美元，最高估計爲114.00美元，低估值爲65.00美元。超過了之前的平均目標價56.00美元，目前的平均價格上漲了70.84％。
Exploring Analyst Ratings: An In-Depth Overview
探索分析師評級：深入概述
The analysis of recent analyst actions sheds...
對分析師近期行...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。